Integrated multi-omics approach identified molecular mechanism and pathogenetic processes of COVID-19 that affect patient with Parkinson's disorder

The novel coronavirus named SARS-CoV-2 has emerged at the end of 2019, which causes coronavirus disease (COVID-2019). Recent case reports of SARS-CoV-2 infected individuals have revealed the onset of Parkinson's disease (PD) symptoms in patients who do not have a family history of the PD.. However, till recently, no genetic impact or mechanisms that may induce Parkinsonism inCOVID-19 patients or after COVID-19 have been found.. This study aimed to detect the commonly dysregulated genes, transcriptional regulators, and pathways between PD and SARS-CoV-2 infections. We integrated genome-wide transcriptomic datasets from PBMC samples from COVID-19 and PD and associated pathways. Our study revealed 81 upregulated and 48 downregulated differentially expressed genes (DEGs) shared between PD and SARS-CoV-2 infections. These dysregulated genes were involved in key pathways "mitochondrion structure organization", "cell activation in immune response", and "signalling by interleukins". Our analysis showed RELA, TP53 and SP1 TFs that may regulate the upregulated DEGs. We have discovered key dysregulated genes and characterized the biological processes of commonly dysregulated in SARS-CoV-2 infections and PD, which could be used for the design of personalized treatment of PD following COVID-19.